Our News
Alnylam Awarded 2026 Scientific Impact Award by MassBio
Award from Massachusetts biotechnology organization recognizes Alnylam's pioneering leadership in RNA interference (RNAi)
March 26, 2026
Alnylam was honored this week at the annual MassBio State of Possible Conference, one of Massachusetts’ premier gatherings of biotechnology leaders, innovators, and policymakers focused on advancing the next generation of scientific breakthroughs.
During the conference, Alnylam received the Scientific Impact Award, recognizing organizations who have made a profound impact on a field of study, therapeutic area, or patient population through a scientific or commercial breakthrough.
MassBio, the Massachusetts Biotechnology Council, is the industry association supporting Massachusetts’ biotechnology and life sciences ecosystem, bringing together industry, academia, and government to advance innovation and improve patient lives.
MassBio recognized Alnylam for its pioneering work in RNA interference (RNAi) which translated the Nobel Prize-winning discovery of RNAi into RNAi therapeutics - innovative new class of medicine that has resulted in approval of six* Alnylam-developed medicines for patients. This award also recognizes Alnylam's leadership position within the Massachusetts life sciences ecosystem and our contributions to the state as one of Massachusetts's largest life sciences employers.
Timothy Maines, Chief Technical Operations and Quality Officer, accepted the award on behalf of Alnylam during the conference.
We invite you to learn more about our company, how we make our medicines and news of recent commitments to further build out our drug manufacturing capabilities within the Commonwealth of Massachusetts
Tags
Leadership, Articles, MassBio, RNAi, RNA interference, Innovation, Manufacturing
Content Types
FOLLOW US
Visit our social channels to learn more about the innovative work we are doing at Alnylam.
